Tuberculosis and Respiratory Diseases

  • 제85권1호
  • /
  • Pages.74-79
  • /
  • 2022
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Chronic Obstructive Pulmonary Disease Is Not Associated with a Poor Prognosis in COVID-19

  • Kim, Youlim (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine) ;
  • An, Tai Joon (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Park, Yong Bum (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital) ;
  • Kim, Kyungjoo (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Cho, Do Yeon (Big Data Research Division, Health Insurance Review and Assessment Service) ;
  • Rhee, Chin Kook (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Yoo, Kwang-Ha (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine)
  • 투고 : 2021.08.03
  • 심사 : 2021.10.15
  • 발행 : 2022.01.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The effect of underlying chronic obstructive pulmonary disease (COPD) on coronavirus disease 2019 (COVID-19) during a pandemic is controversial. The purpose of this study was to examine the prognosis of COVID-19 according to the underlying COPD. Methods: COVID-19 patients were assessed using nationwide health insurance data. Comorbidities were evaluated using the modified Charlson Comorbidity Index (mCCI) which excluded COPD from conventional CCI scores. Baseline characteristics were assessed. Univariable and multiple logistic and linear regression analyses were performed to determine effects of variables on clinical outcomes. Ages, sex, mCCI, socioeconomic status, and underlying COPD were selected as variables. Results: COPD patients showed older age (71.3±11.6 years vs. 47.7±19.1 years, p<0.001), higher mCCI (2.6±1.9 vs. 0.8±1.3, p<0.001), and higher mortality (22.9% vs. 3.2%, p<0.001) than non-COPD patients. The intensive care unit admission rate and hospital length of stay were not significantly different between the two groups. All variables were associated with mortality in univariate analysis. However, underlying COPD was not associated with mortality unlike other variables in the adjusted analysis. Older age (odds ratio [OR], 1.12; 95% confidence interval [CI], 1.11-1.14; p<0.001), male sex (OR, 2.29; 95% CI, 1.67-3.12; p<0.001), higher mCCI (OR, 1.30; 95% CI, 1.20-1.41; p<0.001), and medical aid insurance (OR, 1.55; 95% CI, 1.03-2.32; p=0.035) were associated with mortality. Conclusion: Underlying COPD is not associated with a poor prognosis of COVID-19.

키워드

과제정보

This research was supported by a grant (HI18C0522) from the Korea Health Technology R&D Project through the Korean Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea.

참고문헌

  1. Leung JM, Niikura M, Yang CW, Sin DD. COVID-19 and COPD. Eur Respir J 2020;56:2002108. https://doi.org/10.1183/13993003.02108-2020
  2. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med 2020;201:1380-8. https://doi.org/10.1164/rccm.202002-0445oc
  3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20. https://doi.org/10.1056/NEJMoa2002032
  4. Sin DD. COVID-19 in COPD: a growing concern. EClinicalMedicine 2020;26:100546. https://doi.org/10.1016/j.eclinm.2020.100546
  5. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014;36:e2014008.
  6. Rhee CK, Kim K, Yoon HK, Kim JA, Kim SH, Lee SH, et al. Natural course of early COPD. Int J Chron Obstruct Pulmon Dis 2017;12:663-8. https://doi.org/10.2147/COPD.S122989
  7. Park SC, Kim YS, Kang YA, Park EC, Shin CS, Kim DW, et al. Hemoglobin and mortality in patients with COPD: a nationwide population-based cohort study. Int J Chron Obstruct Pulmon Dis 2018;13:1599-605. https://doi.org/10.2147/COPD.S159249
  8. Lim JU, Kim K, Kim SH, Lee MG, Lee SY, Yoo KH, et al. Comparative study on medical utilization and costs of chronic obstructive pulmonary disease with good lung function. Int J Chron Obstruct Pulmon Dis 2017;12:2711-21. https://doi.org/10.2147/COPD.S143244
  9. Lee J, Lee JH, Kim JA, Rhee CK. Trend of cost and utilization of COPD medication in Korea. Int J Chron Obstruct Pulmon Dis 2017;12:27-33. https://doi.org/10.2147/COPD.S121687
  10. Kim JA, Lim MK, Kim K, Park J, Rhee CK. Adherence to inhaled medications and its effect on healthcare utilization and costs among high-grade chronic obstructive pulmonary disease patients. Clin Drug Investig 2018;38:333-40. https://doi.org/10.1007/s40261-017-0612-2
  11. Jo YS, Kim YH, Lee JY, Kim K, Jung KS, Yoo KH, et al. Impact of BMI on exacerbation and medical care expenses in subjects with mild to moderate airflow obstruction. Int J Chron Obstruct Pulmon Dis 2018;13:2261-9. https://doi.org/10.2147/COPD.S163000
  12. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004;57:1288-94. https://doi.org/10.1016/j.jclinepi.2004.03.012
  13. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, et al. Prevalence, severity and mortality associated with COPD and Smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One 2020;15:e0233147. https://doi.org/10.1371/journal.pone.0233147
  14. Halpin DM, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J 2020;55:2001009. https://doi.org/10.1183/13993003.01009-2020